TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that after extensive preclinical screening studies…


Previous articlePharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
Next articleCOMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022